Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should KnowZacks Investment Research • 07/13/23
Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer StudyZacks Investment Research • 07/12/23
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 TrialBusiness Wire • 07/11/23
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience PartnershipAccesswire • 07/11/23
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%Business Wire • 06/29/23
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)PRNewsWire • 06/28/23
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 06/26/23